EORTC
Business Services · Belgium · 201-500 Employees
View Company Info for Free
Overview
Headquarters
Rue Du Marché Aux Poulet 32 b, Brussels,...Phone Number
+32 27741611Website
www.eortc.orgRevenue
$24 MillionIndustry
About EORTC
EORTC Org Chart
Is EORTC your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once EORTC has new funding data
Website visits: Recent activity has been detected on your website
EORTC, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if EORTC is spiking on competitors!
Click to see if EORTC had a recent Job posting/layoffs
Check if EORTC has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on EORTC recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at EORTC
Product Launch: Get notified when EORTC launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
EORTC is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
EORTC is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about EORTC.
EORTC Tech Stack
A closer look at the technologies used by EORTC
Most Recent Scoops
EORTC News & Media
Aulos Bioscience Presents Phase 2 Dose Selection Data for Novel IL-2 Therapeutic Antibody, AU-007, at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today shared data and analyses used to determine dose selection for Phase 2 expansion cohorts in a Phase 1/2 clinical trial of its lead candidate, AU-007. The data and evaluations of pharmacodynamics, pharmacokinetics, safety and clinical efficacy were presented as a poster at the 36th EORTC-NCI-AACR Symposium onHMP Global and EORTC announce partnership for the 25th annual World Congress on Gastrointestinal Cancer
EORTC will coordinate symposium and workshop for young investigators; more than 3,000 delegates expected at the 28 June – 1 July event in Barcelona, Spain. MALVERN, PENNSYLVANIA, UNITED STATES, April 25, 2023 /EINPresswire.com/ -- HMP Global, the …Promontory Therapeutics Reports PT-112's Effects on Human Prostate Cancer Cell Mitochondria at the 34th EORTC-NCI-AACR Symposium
NEW YORK, Oct. 26, 2022 /PRNewswire/ -- Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing small molecule immunotherapies in oncology, reported today new non-clinical data on its lead candidate, immunogenic cell death inducer PT-112, and its effects on human...
Top Business Services Companies
Frequently Asked Questions Regarding EORTC
The European Organisation for Research and Treatment of Cancer (EORTC) is dedicated to advancing clinical research in oncology, with a focus on improving patient outcomes through innovative studies. With a network of over 4,000 members across 63 countries, EORTC conducts numerous clinical trials and provides education and training for young investi... Read More